OTCMKTS:NRXGQ - NephroGenex Stock Price, Price Target & More

$0.0028 0.00 (0.00 %)
(As of 04/25/2018 06:37 AM ET)
Previous Close$0.0028
Today's Range$0.0028 - $0.0028
52-Week Range$0.0020 - $0.21
Volume2,000 shs
Average Volume26,223 shs
Market Capitalization$36,250.00
P/E RatioN/A
Dividend YieldN/A

About NephroGenex (OTCMKTS:NRXGQ)

NephroGenex logoNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Receive NRXGQ News and Ratings via Email

Sign-up to receive the latest news and ratings for NRXGQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-211.97%
Return on Assets-105.90%


Outstanding Shares12,950,000

How to Become a New Pot Stock Millionaire

NephroGenex (OTCMKTS:NRXGQ) Frequently Asked Questions

What is NephroGenex's stock symbol?

NephroGenex trades on the OTCMKTS under the ticker symbol "NRXGQ."

How were NephroGenex's earnings last quarter?

NephroGenex Inc (OTCMKTS:NRXGQ) released its quarterly earnings data on Wednesday, November, 11th. The healthcare company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.12. View NephroGenex's Earnings History.

Who are NephroGenex's key executives?

NephroGenex's management team includes the folowing people:
  • John P. Hamill CPA, Chief Executive Officer, Chief Financial Officer

Has NephroGenex been receiving favorable news coverage?

News articles about NRXGQ stock have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NephroGenex earned a daily sentiment score of 0.14 on Accern's scale. They also assigned press coverage about the healthcare company an impact score of 45.21 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of NephroGenex?

Shares of NRXGQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NephroGenex's stock price today?

One share of NRXGQ stock can currently be purchased for approximately $0.0028.

How big of a company is NephroGenex?

NephroGenex has a market capitalization of $36,250.00.

How can I contact NephroGenex?

NephroGenex's mailing address is PO Box 400, JAMISON, PA 18929-0400, United States. The healthcare company can be reached via phone at +1-609-5538887.

MarketBeat Community Rating for NephroGenex (NRXGQ)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about NephroGenex and other stocks. Vote "Outperform" if you believe NRXGQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRXGQ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NephroGenex (OTCMKTS:NRXGQ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/ABuyBuyBuy
Consensus Rating Score: N/A3.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$17.50$17.50$17.50
Price Target Upside: N/A12,391.08% upside12,391.08% upside12,391.08% upside

NephroGenex (OTCMKTS:NRXGQ) Consensus Price Target History

Price Target History for NephroGenex (OTCMKTS:NRXGQ)

NephroGenex (OTCMKTS:NRXGQ) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
3/29/2017FBR & CoReiterated RatingOutperform$17.50View Rating Details
(Data available from 4/25/2016 forward)


NephroGenex (OTCMKTS:NRXGQ) Earnings History and Estimates Chart

Earnings by Quarter for NephroGenex (OTCMKTS:NRXGQ)

NephroGenex (OTCMKTS NRXGQ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2015Q315($0.65)($0.53)ViewListenView Earnings Details
8/12/2015Q215($0.56)($0.72)ViewListenView Earnings Details
5/13/2015Q115($0.62)($0.58)ViewN/AView Earnings Details
3/24/2015Q414($0.58)($0.60)ViewN/AView Earnings Details
11/12/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014($0.24)($0.61)ViewN/AView Earnings Details
5/14/2014Q114($0.37)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


NephroGenex (OTCMKTS:NRXGQ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

NephroGenex (OTCMKTS NRXGQ) Insider Trading and Institutional Ownership History

Insider Trading History for NephroGenex (OTCMKTS:NRXGQ)

NephroGenex (OTCMKTS NRXGQ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/6/2015Ventures V L.P. RhoMajor ShareholderSell273,860$10.58$2,897,438.80View SEC Filing  
11/25/2014Bob PetersonVPBuy2,000$4.20$8,400.00View SEC Filing  
2/14/2014Robert R SeltzerDirectorBuy790,000$12.00$9,480,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


NephroGenex (OTCMKTS NRXGQ) News Headlines

Comparing Mylan (MYL) & NephroGenex (NRXGQ)Comparing Mylan (MYL) & NephroGenex (NRXGQ)
www.americanbankingnews.com - December 18 at 1:46 PM
Mylan (MYL) & NephroGenex (NRXGQ) Critical ContrastMylan (MYL) & NephroGenex (NRXGQ) Critical Contrast
www.americanbankingnews.com - December 14 at 11:06 PM
Head-To-Head Comparison: NephroGenex (NRXGQ) vs. Mylan (MYL)Head-To-Head Comparison: NephroGenex (NRXGQ) vs. Mylan (MYL)
www.americanbankingnews.com - December 13 at 3:50 AM
NephroGenex (NRXGQ) and Mylan (MYL) Financial SurveyNephroGenex (NRXGQ) and Mylan (MYL) Financial Survey
www.americanbankingnews.com - December 7 at 7:30 PM
NephroGenex (NRXGQ) versus Mylan (MYL) Head to Head ReviewNephroGenex (NRXGQ) versus Mylan (MYL) Head to Head Review
www.americanbankingnews.com - December 3 at 8:14 AM
NephroGenex (NRXGQ) and Allergan (AGN) Critical ContrastNephroGenex (NRXGQ) and Allergan (AGN) Critical Contrast
www.americanbankingnews.com - December 2 at 5:54 PM
Head to Head Survey: Mylan (MYL) vs. NephroGenex (NRXGQ)Head to Head Survey: Mylan (MYL) vs. NephroGenex (NRXGQ)
www.americanbankingnews.com - November 30 at 1:28 AM
Head to Head Review: Mylan (MYL) and NephroGenex (NRXGQ)Head to Head Review: Mylan (MYL) and NephroGenex (NRXGQ)
www.americanbankingnews.com - November 29 at 7:28 PM
Comparing Mylan (MYL) and NephroGenex (NRXGQ)Comparing Mylan (MYL) and NephroGenex (NRXGQ)
www.americanbankingnews.com - November 28 at 11:40 AM
Analyzing Mylan N.V. (MYL) and NephroGenex (NRXGQ)Analyzing Mylan N.V. (MYL) and NephroGenex (NRXGQ)
www.americanbankingnews.com - November 21 at 11:20 AM
Allergan PLC. (AGN) & NephroGenex (NRXGQ) Head-To-Head ComparisonAllergan PLC. (AGN) & NephroGenex (NRXGQ) Head-To-Head Comparison
www.americanbankingnews.com - November 19 at 7:22 AM
Financial Review: NephroGenex (NRXGQ) vs. Mylan N.V. (MYL)Financial Review: NephroGenex (NRXGQ) vs. Mylan N.V. (MYL)
www.americanbankingnews.com - November 19 at 5:52 AM
NephroGenex (NRXGQ) vs. Allergan PLC. (AGN) Head to Head SurveyNephroGenex (NRXGQ) vs. Allergan PLC. (AGN) Head to Head Survey
www.americanbankingnews.com - November 17 at 5:22 AM
NephroGenex (NRXGQ) vs. Allergan PLC. (AGN) Head to Head ComparisonNephroGenex (NRXGQ) vs. Allergan PLC. (AGN) Head to Head Comparison
www.americanbankingnews.com - November 17 at 1:24 AM
Head-To-Head Survey: Allergan PLC. (AGN) vs. NephroGenex (NRXGQ)Head-To-Head Survey: Allergan PLC. (AGN) vs. NephroGenex (NRXGQ)
www.americanbankingnews.com - November 16 at 10:28 AM

SEC Filings

NephroGenex (OTCMKTS:NRXGQ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


NephroGenex (OTCMKTS:NRXGQ) Income Statement, Balance Sheet and Cash Flow Statement


NephroGenex (OTCMKTS NRXGQ) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.